Apogee Therapeutics (APGE) Long-Term Deferred Tax (2023)

Apogee Therapeutics' (APGE) quarterly Long-Term Deferred Tax came in at $5.4 million in Q4 2023.

Apogee Therapeutics (APGE) Long-Term Deferred Tax (2023) Analysis & Trends

Apogee Therapeutics (APGE) has 1 years of Long-Term Deferred Tax data on file, last reported at $5.4 million in Q4 2023.

On a quarterly basis, Long-Term Deferred Tax changed N/A year-over-year to $5.4 million in Q4 2023; TTM through Dec 2023 was $5.4 million, a N/A change from a year earlier, with the FY2023 full-year figure at $5.4 million, changed N/A from the prior year.
Long-Term Deferred Tax for Q4 2023 stood at $5.4 million.
Over the last five years, Long-Term Deferred Tax for APGE reached as high as $5.4 million in Q4 2023 and fell as low as $5.4 million in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Apogee Therapeutics	9.35 Bn	8.29 Bn	-

Download Data

Date	Value
Dec 31, 2023	5.37 Mn